Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PriceSmart (PSMT) downgraded to Sector Perform from Outperform at Scotia Howard Weil. 2. Teva (TEVA) downgraded to Underperform from Market Perform at Wells Fargo with analyst David Maris saying Teva shares have now risen approximately 80% from its lows in November. 3. Roku (ROKU) downgraded to Sell from Neutral at Citi with analyst Mark May saying the stock is up 266% from its initial public offering price of $14 just three months ago. 4. Johnson Controls (JCI) downgraded to Neutral from Outperform at Baird with analyst Timothy Wojs saying valuation is fair in light of slower growth, lower free-cash flow conversion, and "choppier" execution. 5. Wingstop (WING) downgraded to Neutral from Outperform at Wedbush with analyst Nick Setyan saying while drivers of "solid" low single-digit same-store sales growth in 2018 exist, current consensus estimates may prove "overly optimistic." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Teva Pharmaceuticals announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO. As a fatal, neurodegenerative disease, HD can cause cognitive deterioration, behavioral and/or psychological problems and uncontrollable body movements known as chorea - a symptom that can have a significant impact on daily activities like eating or talking.3-5 These data are being presented at the 2024 American Academy of Neurology AAN Annual Meeting. "90% of HD patients experience chorea,3,4 so it's important for patients to have a treatment option that not only helps address symptoms, but helps provide a positive patient experience," said Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva. "We remain committed to exploring ways to evolve the AUSTEDO treatment experience to meet the needs of the HD community, and these latest real-world data reinforce the role of the 4-week Titration Kit for AUSTEDO in empowering patients with HD chorea to find their optimal dose, adhere consistently to their treatment plan, and achieve effective outcomes."